We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Australia Leads Effort To Improve Diagnosis of Genetic Disorders

By LabMedica International staff writers
Posted on 17 Nov 2008
Australian scientists are leading a global initiative to improve the diagnosis of genetic disorders and reduce errors in the reporting of genetic variations. More...


Over 60% of people worldwide will be affected by a genetic change at some point in their lives that can result in a range of diseases such as cystic fibrosis, epilepsy, and cancer.

The Human Genome Project completed in early 2000, succeeded mapping the human genome. However, of the 20,000 human genes mapped, only 3,000 have any information available on their variations.

The Australian-led global project, called the Human Variome Project, is being conducted by University of Melbourne (Australia) investigators and colleagues within the Florey Neuroscience Institutes (Melbourne, Australia), the department of medicine at the Royal Melbourne Hospital (Melbourne, Australia), and the Epilepsy Research Center (Melbourne, Australia), together with other scientists from around the globe.

The global initiative was published in the November 2006 issue of the journal Science. Prof. Richard Cotton, lead author of the study, convener of the Human Variome Project, and honorary researcher at the University of Melbourne said, "There is a staggering error rate of up to 40% [in] some reporting of genetic variations. This means clinicians and specialists cannot solely rely on the research literature to inform the life and death decisions of diagnosis and prognosis of genetic disorders.”

The Human Variome Project will produce standards for the storage, transmission, and use of genetic variation information, which for many will reduce the enormously time-consuming task of seeking data to assist in providing patients with information.

A range of pilot projects are being organized around the world that will examine how to systematically collect genetic, clinical, and biochemical information in either a country- specific or gene-specific manner. Countries already planning to participate in these projects include Australia, China, Japan, and Kuwait.

The project has the support of World Health Organization (WHO; Geneva, Switzerland), the United Nations Scientific and Cultural Organization (UNESCO), and the Organization for Economic Cooperation and Development (OECD) countries.

Related Links:
University of Melbourne
Florey Neuroscience Institutes
Department of Medicine at the Royal Melbourne Hospital
Epilepsy Research Center
World Health Organization
United Nations Scientific and Cultural Organization
Organization for Economic Cooperation and Development


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image

Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms

Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.